Citadel Advisors
RPRX

Citadel Advisors’s Repros Therapeutics Inc. RPRX Stock Holding History

Citadel Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-15,518
Closed -$10K – 9302
2017
Q4 		$10K Buy
+15,518
New +$7.83K ﹤0.01% 7894
2016
Q2 		– Sell
-31,535
Closed -$60.5K – 8054
2016
Q1 		$31K Sell
31,535
-44,070
-58% -$43K ﹤0.01% 6377
2015
Q4 		$92K Buy
+75,605
New +$243K ﹤0.01% 6793
2015
Q2 		– Sell
-3,001
Closed -$23.4K – 9564
2015
Q1 		$26K Sell
3,001
-23,185
-89% -$207K ﹤0.01% 7764
2014
Q4 		$261K Sell
26,186
-88,065
-77% -$751K ﹤0.01% 5637
2014
Q3 		$1.13M Buy
114,251
+107,578
+1,612% +$1.59M ﹤0.01% 3560
2014
Q2 		$115K Sell
6,673
-10,005
-60% -$163K ﹤0.01% 6125
2014
Q1 		$296K Sell
16,678
-1,232,415
-99% -$23.8M ﹤0.01% 5042
2013
Q4 		$22.9M Sell
1,249,093
-87,113
-7% -$1.65M 0.03% 729
2013
Q3 		$35.8M Buy
1,336,206
+655,384
+96% +$14M 0.05% 444
2013
Q2 		$12.6M Buy
+680,822
New +$12M 0.02% 917

Citadel Advisors's RPRX Position: Q1 2018 in Review

Citadel Advisors sold out of Repros Therapeutics Inc. (RPRX) in Q1 2018, closing a stake of 15,518 shares — an estimated $10K sold.

Citadel Advisors first reported a position in RPRX in Q2 2013 and held it in 11 quarters. The position peaked at $35.8M in Q3 2013. 1 fund tracked by Wall St. Rank holds RPRX as of Q1 2018.

  • Citadel Advisors reported no remaining Repros Therapeutics Inc. position as of Q1 2018 after selling out during the quarter.
  • Citadel Advisors sold 15,518 Repros Therapeutics Inc. shares in Q1 2018, an estimated $10K.
  • Citadel Advisors first reported a position in Repros Therapeutics Inc. in Q2 2013 and held it in 11 quarters.
  • Citadel Advisors's Repros Therapeutics Inc. position peaked at $35.8M in Q3 2013.
  • 1 fund tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q1 2018.

Based on Citadel Advisors's 13F filing for Q1 2018, filed 11 May 2018.